Stool test strategy aims to prevent UC Flare-Ups

NCT ID NCT07402135

Not yet recruiting Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using stool biomarkers (fecal calprotectin and fecal immunochemical test) to guide treatment adjustments can prevent relapses in people with ulcerative colitis. About 240 adults in remission will be randomly assigned to either biomarker-guided therapy or usual care. The goal is to see if early treatment changes based on stool test results can reduce the risk of flare-ups, hospitalizations, or surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal biomarker-guided therapy escalation (procedure)
What this could lead to: If successful, this approach could help doctors adjust treatment earlier based on stool test results, potentially preventing flare-ups and reducing hospitalizations.
What could go wrong: This is an early-stage strategy trial with no direct treatment benefit. The approach may not improve outcomes over usual care, and the open-label design could introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONINVASIVE BIOMARKERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NONINVASIVE BIOMARKERS ULCERATIVE COLITIS (UC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.